e-Therapeutics plc

e-Therapeutics 'purposefully going out to the world' to engage with big pharma

Ray Barlow, chief executive of e-Therapeutics plc (LON:ETX) caught up with Proactive to update on developments at the drug developer.

Last month they unveiled the results of its strategic review under the new chief executive.

Following the review, the company decided to invest in its network-driven drug discovery (NDD) platform in creating new drugs, while continuing to control costs.

''The first three months of my tenure have been internally-facing .. we're now very purposefully going out to the world'', Barlow says.

''We're going to undertake a very  systematic business development exercise, we're going to engage with biopharmaceutical companies ... we're also going to engage with companies that may not be traditionally associated with this space - such as the googles of this world''.

Quick facts: e-Therapeutics plc

Price: £0.03

Market: AIM
Market Cap: £7.05 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of e-Therapeutics plc named herein, including the promotion by the Company of e-Therapeutics plc in any Content on the Site, the Company receives...


2 min read